{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:52:05Z","timestamp":1744357925285},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a scarcity of information on the population with diabetes mellitus type 2 and cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic medications and COVID-19 outcomes. Study is designed as a retrospective cohort analysis covering 2020 and 2021. Data from National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths. For outcome predictors, logistic regression models were developed. Of 231 796 patients with diabetes mellitus type 2 in the database, 14 485 patients had cardiomyopathy. The two2-year cumulative incidence of all three studies' COVID-19 outcomes was higher in PDMC than in the general diabetes population (positivity 15.3% vs. 14.6%, p\u2009=\u20090.01; hospitalization 7.8% vs. 4.4%, p\u2009&lt;\u20090.001; death 2.6% vs. 1.2%, p\u2009&lt;\u20090.001). Sodium-Glucose Transporter 2 (SGLT-2) inhibitors therapy was found to be protective of SARS-CoV-2 infections [OR 0.722 (95% CI 0.610\u20130.856)] and COVID-19 hospitalizations [OR 0.555 (95% CI 0.418\u20130.737)], sulfonylureas to be risk factors for hospitalization [OR 1.184 (95% CI 1.029\u20131.362)] and insulin to be a risk factor for hospitalization [OR 1.261 (95% CI 1.046\u20131.520)] and death [OR 1.431 (95% CI 1.080\u20131.897)]. PDMC are at greater risk of acquiring SARS-CoV-2 infection and having worse outcomes than the general diabetic population. SGLT-2 inhibitors therapy was a protective factor against SARS-CoV-2 infection and against COVID-19 hospitalization, sulfonylurea was the COVID-19 hospitalization risk factor, while insulin was a risk factor for all outcomes. Further research is needed in this diabetes sub-population.<\/jats:p>","DOI":"10.1038\/s41598-024-57871-9","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:01:52Z","timestamp":1711526512000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy"],"prefix":"10.1038","volume":"14","author":[{"given":"Jelena","family":"Dimnjakovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Buble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pero","family":"Ivanko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Prista\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ognjen","family":"Brborovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Brborovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"8","key":"57871_CR1","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/dom.14388","volume":"23","author":"X Cai","year":"2021","unstructured":"Cai, X. et al. Prediabetes and the risk of heart failure: A meta-analysis. Diabetes Obes. Metab. 23(8), 1746\u20131753 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"57871_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2337\/dc20-0941","volume":"43","author":"A Ceriello","year":"2020","unstructured":"Ceriello, A. et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 43(7), 1427\u20131432 (2020).","journal-title":"Diabetes Care."},{"key":"57871_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108151","volume":"163","author":"A Ceriello","year":"2020","unstructured":"Ceriello, A., Stoian, A. P. & Rizzo, M. COVID-19 and diabetes management: What should be considered?. Diabetes Res. Clin. Pract. 163, 108151 (2020).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"57871_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/1932296820930025","volume":"14","author":"A Ceriello","year":"2020","unstructured":"Ceriello, A. & Schnell, O. COVID-19: Considerations of diabetes and cardiovascular disease management. J. Diabetes Sci. Technol. 14(4), 723\u2013724 (2020).","journal-title":"J. Diabetes Sci. Technol."},{"issue":"1","key":"57871_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12933-021-01408-1","volume":"20","author":"A Ceriello","year":"2021","unstructured":"Ceriello, A. et al. Heart failure in type 2 diabetes: Current perspectives on screening, diagnosis and management. Cardiovasc. Diabetol. 20(1), 218 (2021).","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"57871_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia, G., Hill, M. A. & Sowers, J. R. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ. Res. 122(4), 62 (2018).","journal-title":"Circ. Res."},{"issue":"7","key":"57871_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379(7), 633\u2013644 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"57871_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.rce.2020.05.017","volume":"221","author":"F Martos P\u00e9rez","year":"2021","unstructured":"Martos P\u00e9rez, F. et al. Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. Rev. Clin. Esp. 221(9), 529\u2013535 (2021).","journal-title":"Rev. Clin. Esp."},{"issue":"1","key":"57871_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-021-02589-4","volume":"23","author":"N Kaur","year":"2022","unstructured":"Kaur, N., Oskotsky, B., Butte, A. J. & Hu, Z. Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients. Genome Biol. 23(1), 15 (2022).","journal-title":"Genome Biol."},{"issue":"1","key":"57871_CR10","first-page":"74","volume":"57","author":"T Poljicanin","year":"2021","unstructured":"Poljicanin, T., Bralic Lang, V., Mach, Z. & Svajda, M. Croatian diabetes registry (CroDiab) and implementation of standardised diabetes checklists using joint action CHRODIS recommendations and criteria. Ann. Ist. Super Sanita. 57(1), 74\u201379 (2021).","journal-title":"Ann. Ist. Super Sanita."},{"issue":"3","key":"57871_CR11","first-page":"185","volume":"59","author":"T Poljicanin","year":"2005","unstructured":"Poljicanin, T., Pavli\u0107-Renar, I. & Metelko, Z. CroDiab NET\u2013registar osoba sa \u0161e\u0107ernom bolesti [CroDiab NET\u2013electronic diabetes registry]. Acta Med. Croat. 59(3), 185\u2013189 (2005) (Croatian).","journal-title":"Acta Med. Croat."},{"key":"57871_CR12","unstructured":"Polji\u010danin, T. & Prista\u0161, I. National Public Health Information System in Croatia. International Public Health Conference \"Health Indicators as an Important Tool for Strengthening Health Information Systems in the European Region\" Tirana, Albania (2016)."},{"issue":"3\u20134","key":"57871_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijmedinf.2005.08.007","volume":"75","author":"M Kon\u010dar","year":"2006","unstructured":"Kon\u010dar, M. & Gvozdanovi\u0107, D. Primary healthcare information system: The cornerstone for the next generation healthcare sector in Republic of Croatia. Int. J. Med. Inform. 75(3\u20134), 306\u2013314 (2006).","journal-title":"Int. J. Med. Inform."},{"issue":"6","key":"57871_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3325\/cmj.2020.61.481","volume":"61","author":"K Capak","year":"2020","unstructured":"Capak, K. et al. Surveillance system for coronavirus disease 2019 epidemiological parameters in Croatia. Croat. Med. J. 61(6), 481\u2013482 (2020).","journal-title":"Croat. Med. J."},{"key":"57871_CR15","first-page":"95","volume":"15","author":"N Antoljak","year":"2021","unstructured":"Antoljak, N. & Erceg, M. Zna\u010daj digitalizacije podataka prijave uzroka smrti za unapre\u0111enje kvalitete epidemiolo\u0161kog nadzora [Role of digitalized death reports in epidemiological surveillance quality]. Med. Inform. 15, 95 (2021) (Croatian).","journal-title":"Med. Inform."},{"key":"57871_CR16","unstructured":"Croatian Institute of Public Health (CIPH). National Registry of Patients with Diabetes (CroDiab). Report for Year 2020. https:\/\/www.hzjz.hr\/wp-content\/uploads\/2021\/05\/Izvje%C5%A1%C4%87e-za-2020.-godinu.pdf. Accessed 26 Mar 2023"},{"issue":"6","key":"57871_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3325\/cmj.2020.61.518","volume":"61","author":"K Capak","year":"2020","unstructured":"Capak, K. et al. Prevalence of somatic comorbidities among coronavirus disease 2019 patients in Croatia in the first pandemic wave: Data from national public health databases. Croat. Med. J. 61(6), 518\u2013524 (2020).","journal-title":"Croat. Med. J."},{"issue":"11","key":"57871_CR18","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1111\/dom.14490","volume":"23","author":"L Mai","year":"2021","unstructured":"Mai, L. et al. Association between prediabetes and adverse outcomes in heart failure. Diabetes Obes. Metab. 23(11), 2476\u20132483 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"57871_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107, P. M. et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 20(5), 853\u2013872 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"57871_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708494","volume":"12","author":"C Kan","year":"2021","unstructured":"Kan, C. et al. Mortality risk of anti-diabetic agents for type 2 diabetes with COVID-19: A systematic review and meta-analysis. Front. Endocrinol. 12, 708494 (2021).","journal-title":"Front. Endocrinol."},{"key":"57871_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.895458","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Lv, X., Lin, S., Arshad, M. & Dai, M. the association between anti-diabetic agents and clinical outcomes of COVID-19 patients with diabetes: A Bayesian network meta-analysis. Front. Endocrinol. 13, 895458 (2022).","journal-title":"Front. Endocrinol."},{"issue":"5","key":"57871_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.pcd.2021.08.001","volume":"15","author":"A Elibol","year":"2021","unstructured":"Elibol, A. et al. Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus. Prim. Care Diabetes. 15(5), 806\u2013812 (2021).","journal-title":"Prim. Care Diabetes."},{"issue":"12","key":"57871_CR23","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.2337\/dc20-1340","volume":"43","author":"M Mirani","year":"2020","unstructured":"Mirani, M. et al. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: A case series from an academic hospital in Lombardy Italy. Diabetes Care. 43(12), 3042\u20133049 (2020).","journal-title":"Diabetes Care."},{"issue":"2","key":"57871_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.numecd.2020.09.028","volume":"31","author":"GA Silverii","year":"2021","unstructured":"Silverii, G. A. et al. Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr. Metab. Cardiovasc. Dis. 31(2), 396\u2013398 (2021).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"4","key":"57871_CR25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00125-020-05351-w","volume":"64","author":"M Wargny","year":"2021","unstructured":"Wargny, M. et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: Updated results from the nationwide CORONADO study. Diabetologia. 64(4), 778\u2013794 (2021).","journal-title":"Diabetologia."},{"issue":"2","key":"57871_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/dom.14256","volume":"23","author":"H Sourij","year":"2021","unstructured":"Sourij, H. et al. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes. Metab. 23(2), 589\u2013598 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"57871_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155196","volume":"131","author":"NN Nguyen","year":"2022","unstructured":"Nguyen, N. N. et al. Preadmission use of anti-diabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 131, 155196 (2022).","journal-title":"Metabolism."},{"issue":"2","key":"57871_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.arcmed.2021.08.002","volume":"53","author":"T Han","year":"2022","unstructured":"Han, T. et al. Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: A systematic review and meta-analysis. Arch. Med. Res. 53(2), 186\u2013195 (2022).","journal-title":"Arch. Med. Res."},{"issue":"11","key":"57871_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14833","volume":"75","author":"N Katsiki","year":"2021","unstructured":"Katsiki, N., Gomez-Huelgas, R., Mikhailidis, D. P. & Perez-Martinez, P. Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. Int. J. Clin. Pract. 75(11), e14833 (2021).","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"57871_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/1753-0407.13359","volume":"15","author":"M Nassar","year":"2023","unstructured":"Nassar, M., Abosheaishaa, H., Singh, A. K., Misra, A. & Bloomgarden, Z. Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. J. Diabetes. 15(2), 86\u201396 (2023).","journal-title":"J. Diabetes."},{"issue":"6","key":"57871_CR31","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/bcp.15258","volume":"88","author":"A Ganesh","year":"2022","unstructured":"Ganesh, A. & Randall, M. D. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 88(6), 2642\u20132656 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"57871_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pcd.2021.12.008","volume":"16","author":"AFMZ Zein","year":"2022","unstructured":"Zein, A. F. M. Z. & Raffaello, W. M. Dipeptidyl peptidase-4 (DPP-4) inhibitor was associated with mortality reduction in COVID-19: A systematic review and meta-analysis. Prim. Care Diabetes. 16(1), 162\u2013167 (2022).","journal-title":"Prim. Care Diabetes."},{"key":"57871_CR33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","volume":"8","author":"SR Bornstein","year":"2020","unstructured":"Bornstein, S. R. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8, 546\u2013550 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"57871_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/JCMA.0000000000000354","volume":"83","author":"CF Chen","year":"2020","unstructured":"Chen, C. F. et al. Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. J. Chin. Med. Assoc. 83(9), 809\u2013811 (2020).","journal-title":"J. Chin. Med. Assoc."},{"key":"57871_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110205","volume":"195","author":"H Permana","year":"2023","unstructured":"Permana, H., Audi Yanto, T. & Ivan, H. T. Preadmission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression. Diabetes Res. Clin. Pract. 195, 110205 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"9","key":"57871_CR36","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod, M. N. et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9(9), 586\u2013594 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"57871_CR37","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/dom.14329","volume":"23","author":"SB Israelsen","year":"2021","unstructured":"Israelsen, S. B. et al. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes. Metab. 23(6), 1397\u20131401 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"57871_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2337\/dc21-0065","volume":"44","author":"AR Kahkoska","year":"2021","unstructured":"Kahkoska, A. R. et al. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 44(7), 1564\u20131572 (2021).","journal-title":"Diabetes Care."},{"issue":"2","key":"57871_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/v15020533","volume":"15","author":"MZ Yan","year":"2023","unstructured":"Yan, M. Z., Yang, M. & Lai, C. L. Post-COVID-19 syndrome comprehensive assessment: From clinical diagnosis to imaging and biochemical-guided diagnosis and management. Viruses. 15(2), 533 (2023).","journal-title":"Viruses."},{"key":"57871_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2023.2279699","volume":"1","author":"N Krishna","year":"2023","unstructured":"Krishna, N. Identifying diseases associated with post-COVID syndrome through an integrated network biology approach. J. Biomol. Struct. Dyn. 1, 1\u201320 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"57871_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ecl.2004.11.001","volume":"34","author":"ES Moghissi","year":"2005","unstructured":"Moghissi, E. S. & Hirsch, I. B. Hospital management of diabetes. Endocrinol. Metab. Clin. N. Am. 34(1), 99\u2013116 (2005).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"57871_CR42","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","volume":"14","author":"N Li","year":"2020","unstructured":"Li, N. & Zhou, H. SGLT2 inhibitors: A novel player in the treatment and prevention of diabetic cardiomyopathy. Drug Des. Dev. Ther. 14, 4775\u20134788 (2020).","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"57871_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/biomedicines8030043","volume":"8","author":"AM Hussein","year":"2020","unstructured":"Hussein, A. M. et al. Comparative study of the effects of GLP1 analog and SGLT-2 Inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: Possible underlying mechanisms. Biomedicines. 8(3), 43 (2020).","journal-title":"Biomedicines."},{"issue":"1","key":"57871_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-020-01042-3","volume":"19","author":"IC Hwang","year":"2020","unstructured":"Hwang, I. C. et al. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc. Diabetol. 19(1), 69 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"10254","key":"57871_CR45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 396(10254), 819\u2013829 (2020).","journal-title":"Lancet."},{"key":"57871_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2021.704807","volume":"2","author":"I Cerove\u010dki","year":"2021","unstructured":"Cerove\u010dki, I. & \u0160vajda, M. COVID-19 pandemic influence on diabetes management in Croatia. Front. Clin. Diabetes Healthc. 2, 704807 (2021).","journal-title":"Front. Clin. Diabetes Healthc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57871-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:05:02Z","timestamp":1711526702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57871-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57871"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57871-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7227"}}